Dana Yarden

Dana Yarden has an extensive work experience in the life sciences industry. Starting in 2005, they worked as an Executive Director of Medical Affairs, Drug Development Manager, and Medical Director at BioLineRx. In 2010, they joined CollPlant as Executive Director of Clinical & BD Affairs. That same year, they also began working as a Manager for the Health Administration Program, a joint endeavor of the Faculty of Management and the Faculty of Medicine. In 2011, they became the CEO of Omer Therapeutics, a small, privately owned company involved in developing a preventive treatment for allergic disorders. In 2012, they co-founded both BioBetter\u2122 and Anatomy - a medical device VC. In 2013, they became the CEO of SmartWave Medical, a company that develops a new treatment approach for atrial fibrillation. Finally, in 2014, they co-founded GemmaCert and became the Executive Director of WuXi AppTec, a leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company.

Dana Yarden completed an MBA from Tel Aviv University between 2006 and 2008. Prior to that, they completed an MHA from Tel Aviv University between 2004 and 2006. Yarden also completed an MD from Tel Aviv University between 1997 and 2005.